1 / 30

HT in Slovenia in the last decade - risks and benefits

HT in Slovenia in the last decade - risks and benefits. Damir Franić MD PhD, Slovenia Prof. Helena Meden-Vrtovec MD PhD, Slovenia Ivan Verdenik PhD, Slovenia. VI Hrvaško-slovenski simpozij o menopavzi in andropavzi – Brijuni, 08.-11.09.2011. HT – the story of “bipolar disorder”.

gustav
Download Presentation

HT in Slovenia in the last decade - risks and benefits

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HT in Slovenia in the last decade - risks and benefits Damir Franić MD PhD, Slovenia Prof. Helena Meden-Vrtovec MD PhD, Slovenia Ivan Verdenik PhD, Slovenia VI Hrvaško-slovenski simpozij o menopavzi in andropavzi – Brijuni, 08.-11.09.2011

  2. HT – the story of “bipolar disorder” Observational studies - NHS R. Wilson. – “Feminine forever” ? 2002 1960 1963 1970 1980 1990 2011 Unopposed E, endometrial hyperplasia atypical hyperplasia, endom. Ca RCT - WHI

  3. Post WHI era Pre WHI eraBenefits and risks of HT • Symptomrelief (QoL) • Urogenital atrophy • Osteoporosis • Cardiovascular • Neuro-cognitive • Colorectal cancer Risks Benefits • Breast cancer • Endometrial cancer • Thromboembolism • Gallbladder disease

  4. Strength of Recommendation Decreased RR Vasomotor Symptoms Genitourinary Symptoms Cardiovascular Disease Hip and Vertebral Fracture Alzheimer’s Disease Colorectal Cancer Tooth Loss Breast Cancer Mortality Death < Age 80 A A A A BB B B B Evidence-Based Benefits of ERT Level of Evidence I II-2 II-2 II-2 II-2 II-2 II-2 II-2 II-2

  5. Level of Evidence Strength ofRecommendation Increased RR Endometrial Cancer II-2 A VTE II-2 B Breast Cancer Diagnosis II-2 C2 Gallbladder Disease II-2 C2 Evidence-Based Hazards of ERT

  6. Statisticaly significant cumulative incidence rates for clinical outcomes in the WHI E alone trial HR (95%CI) Favors CEE Favors placebo P value Event by Age group (y) CHD 50-590,59 (0,38-0,90) 0,05 60-69 1,00 (0,80-1,24) 70-79 1,06 (0,82-1,36) Total MI 50-590,54 (0,34-0,86) 60-69 1,05 (0,82-1,35) 0,007 70-79 1,23 (0,92-1,65) Colorectal cancer 50-590,80 (0,40-1,61) 60-69 0,90 (0,58-1,39) 0,04 70-79 1,83 (1,08-3,12) Death (all causes) 50-59 0,73 (0,53-1,00) 60-69 1,04 (0,88-1,24) 0,04 70-79 1,12 (0,94-1,33) Global index 50-590,85 (0,70-1,03) 60-69 1,00 (0,89-1,13) 0,009 70-79 1,15( 1,01-1,32) 0,4 1,0 2,0 3,0 Modified from: LaCroix et al: JAMA 2011;305(13):1305

  7. HT “ever users” 1998 - 2007 Barbaglia G et al. Menopause 2009;16(5):1061-64

  8. New HT users 1998-2007 Barbaglia G et al. Menopause 2009;16(5):1061-64.

  9. HT in Slovenia – 3 points of view National Health Insurance Database (2001-2009) National Women’s Survey “Menopausis in Slovenia” (1999;2009) Slovenian Adherence Study (2003 – 2005)

  10. National Health Insurance Database (2001-2009) No. of women age 40-65 = 349,864 Number of Prescriptions (Rp) Daily defined dose (DDD) Number of packages

  11. Daily Defined Dose (DDD) • The basic definition of the defined daily dose (DDD) is: • The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. • A DDD will only be assigned for drugs that already have an ATC code

  12. “Current users” and “Ever users” • Evaluation that at least one HT prescription was prescribed – “ever users” (3 months of HT use) • Evaluation that at least two HT prescriptions were prescribed – “current users” – (6 months of HT use)

  13. Local HT, patch, and tibolon use from 2001-2009 in Slovenia(No. of package )

  14. Local HT, patch and tibolon use from 2001-2009 in Slovenia (DDD)

  15. Number of prescription – local HT and tibolon

  16. CC, SC, SCy HT use in Slovenia from 2001 – 2009 ( No. of package)

  17. CC, SC, SCy HT use in Slovenia from 2001 – 2009 (DDD)

  18. Number of prescriptions for CC, SC and SCy - % “ever users”, (“current users”) 14,3% ( 7,54%) 5,4% (2,86%)

  19. National Women’s Survey “Menopausis in Slovenia” (1999;2009)

  20. Survey 1990

  21. Duration of HT use

  22. Satisfaction with HT

  23. Slovenian Adherence Study (2003 – 2005)

  24. Flowchart of the study. Franić D, et al, Effect of counseling on adherence to perimenopausal hormone therapy in Slovenia, Int J Gynecol Obstet (2010) in press Franić et al. Int J Gynaecol Obstet. 2010 Dec;111(3):260-3.

  25. Difference in drop-outs according to time of use (14,4%) (9,7%) (54%) (44,5%) Franić et al. Int J Gynaecol Obstet. 2010 Dec;111(3):260-3.

  26. Conclusion • The expected decrease of HT use since 2003 for systemic HT (NHID) • Stabile local HT use (NHID) • 80% satisfaction with HT (NWS) • Age of menopause in Slovenia – 52 (NWS) • Better adherence in the last decade (NWS) • Important impact of counseling on HT adherence – permanent rather than temporary (SAS) • The need to consider whether separate clinical practice guidelines should be developed for the two hormone therapy regimens.

  27. The level of evidence by the US Preventive Services Task Force • Level I Properly randomized, controlled trial. • Level II-1 Well-designed controlled trial but without randomization. • Level II-2 Well-designed cohort or case-control analytic study. • Level II-3 Multiple time series with or without the intervention (eg, cross-sectional and uncontrolled investigational studies). • Level III Meta-analyses; reports from expert committees; descriptive studies and case reports.

  28. WHI – Evolution of Messages From the Investigators 2002 WHI Study stopped: ‘Risks exceed benefits’. The only fundamentally new finding: ‘Substantial risks for cardiovascular disease’, in contrast to observational studies which had consistently shown reduced CHD risk in HRT users. 2003 Re-analysis: ‘[HRT] may increase the risk of CHD’. 2007 Further re-analysis: ‘Women who initiated HRT closer to menopause tended to have reduced CHD risk’. Rossouw 2002; Manson 2003; Rossouw 2007

  29. HRT and CHD: Observational Studies and RCTs Epidemiologic Studies Age=30-55 y Time Since Menopause <6 y Randomized Trials Age <60 y Time Since Menopause <10 y 0.64 0.68 0.5 1.0 Risk Estimate Grodstein F, et al. ProgCardiovascDis 1995;38:199-210.Salpeter S, et al. J Gen Intern Med 2006;21:363-366.

  30. Physicians practice and attitudes in post WHI era • WHI was a ground-breaking study that changed clinical practice, including counseling • Physicians varied in their opinions of HT and the scientific evidence – positive or negative • created uncertainty about the risks and benefits of HT – everybody was confused • Called for the use of decision aids • an opportunity to discuss healthy lifestyle options with patients Bush TM et al. Society of General Internal Medicine 2007;22:1311–1316

More Related